RYTELO® (imetelstat) HCP Website | RYTELOHCP RYTELO® (imetelstat) is indicated for treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia
DailyMed - RYTELO- imetelstat sodium injection, powder . . . RYTELO for injection contains imetelstat, an oligonucleotide telomerase inhibitor for intravenous use Imetelstat sodium is a white to off-white or slightly yellow, amorphous, solid powder
Imetelstat (RYTELO) National Drug Mini-Monograph July 2025 References RYTELO (imetelstat) for intravenous injection [prescribing information online] Foster City, CA: Geron Corporation 6 2024 Available at: rytelo_pi pdf Accessed 12 9 2024
label - Food and Drug Administration RYTELO (imetelstat) for injection is a sterile, preservative-free, white to off-white or slightly yellow lyophilized powder for intravenous infusion after reconstitution and dilution
RYTELO (imetelstat), FDA Approved for Treatment of Patients . . . Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by Geron Corporation as a limited specialty pharmacy provider for RYTELOTM (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring four or more red blood cell units over eight
RYTELO Prescription Dosage Information - MPR RYTELO prescription and dosage information for physicians and health care professionals Pharmacology, adverse reactions, warnings, and RYTELOside effects
HCP Resources - RYTELOHCP Discover additional RYTELO (imetelstat) resources and information for healthcare providers to use with their patients
Rytelo: Uses, Dosage, Side Effects, Warnings - Drugs. com Rytelo (imetelstat) is an injectable telomerase inhibitor that may be used to treat adults with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia